The Journal of Clinical and Aesthetic Dermatology

Dr. Tolkachjov discusses generalized pustular psoriasis (GPP) as a distinct, potentially severe inflammatory disease characterized by widespread sterile pustules, erythema, systemic symptoms, and recurrent flares. He reviews the role of dysregulated IL-36 signaling and downstream neutrophilic inflammation in GPP pathogenesis, and explains how targeting this pathway with spesolimab has changed the treatment approach. Dr. Tolkachjov also highlights the importance of distinguishing GPP from othe...

Dr. Werth reviews 52-week findings from the phase 2 AMETHYST study of litifilimab in patients with moderate-to-severe cutaneous lupus erythematosus (CLE). She highlights the rapid onset of response observed during the randomized portion of the trial and explains that patients who switched from placebo to litifilimab at Week 24 showed improvement within several weeks and subsequently approached the responses seen in patients treated from the outset. Participants who received litifilimab throug...

Dr. Trotter discusses necessary clinical considerations and practical use cases for the treatment of severe alopecia areata with treatments such as deuruxolitinib. She highlights the importance of systemic therapy in patients with severe alopecia areata due primarily to lack of spontaneous remission and risk of disease progression. Additionally, Dr. Trotter identifies best use cases for deuruxolitinib, emphasizes the importance of patient severity assessments such as the Alopecia Areata Scale...

Dr. Khattri looks at the 52-week findings from the ongoing phase 2/3 AMETHYST trial evaluating litifilimab in cutaneous lupus erythematosus (CLE), which were presented at the EADV Congress 2026. She notes that there are currently no FDA-approved targeted therapies for CLE, a disease that can cause permanent scarring, dyspigmentation, and scarring alopecia. Litifilimab, a monoclonal antibody that targets BDCA2, demonstrated continued improvement through 52 weeks rather than plateauing, accordi...

Dr. Brownstone discusses the place of risankizumab in the psoriasis and psoriatic arthritis treatment landscape. He discusses risankizumab’s durable response, infrequent dosing, and favorable long-term and short-term safety profiles. Dr. Brownstone references the UltIMMa-1 (NCT02684370) and UltIMMa-2 (NCT02684357) trials, which demonstrated the superior efficacy of risankizumab vs placebo and ustekinumab in this patient population. Additionally, he cites a recent anecdotal case detailing one ...

Dr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2026 issue of JCAD.

Dr. Günther discusses her poster from the European Academy of Dermatology and Venereology Congress 2026 on transcriptomic analyses of the phase 2 LILAC trial Part B. The study examined how litifilimab affects the underlying biology of cutaneous lupus erythematosus (CLE). RNA sequencing demonstrated broad immune dysregulation in patients with CLE and showed that treatment with litifilimab shifted numerous disease-associated genes toward expression patterns observed in healthy individuals, incl...

Dr. Fakhoury discusses the use of systemic treatment for patients with severe alopecia areata. He highlights data from the THRIVE-AA1 and THRIVE-AA2 clinical trials, which showed effective results with deuruxilitinib vs placebo in this patient population. Additionally, he emphasizes that the indications for severe alopecia areata have expanded to those with a Severity of Alopecia Tool (SALT) score of 20 to 49 and outlined patient populations who could benefit from treatment with deuruxolitini...

Dr. Chovatiya reviews generalized pustular psoriasis (GPP) as a distinct, potentially life-threatening inflammatory dermatosis characterized by acute flares and periods of relative quiescence. He highlights the diagnostic challenges in differentiating GPP from plaque psoriasis and other pustular disorders, as well as the central role of interleukin (IL)-36 pathway dysregulation in driving neutrophilic inflammation. He also reviews the use of intravenous therapy for rapid management of active ...

Dr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2026 issue of JCAD.

Dr. Cohen discusses the treatment of psoriasis in high-impact sites. He outlines how to approach these special considerations and provides treatment options, including the utilization of biologics like risankizumab. He also reviews considerations for unique cases such as nail psoriasis and palmoplantar psoriasis.

Ahead of National Generalized Pustular Psoriasis (GPP) Awareness Day, Dr. Hawkes gives an overview of the distinct clinical and immunologic features of GPP, emphasizing how this rare, life-threatening disease differs from plaque psoriasis in both presentation and underlying pathophysiology. He highlights the central role of interleukin-36 (IL-36) dysregulation in GPP, explains why therapies developed for plaque psoriasis often do not provide adequate control of the disease, and outlines the r...

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the July 2026 issue of JCAD.

Fabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in GPP management.

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2026 issue of JCAD.

Tina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.

Bruce Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University, discusses his extensive experience in treating patients with psoriasis. He describes his experience treating these patients with risankizumab (Skyrizi), highlighting its efficacy in treating chronic plaque psoriasis and its effectiveness for patients with comorbidities. The therapy has shown rapid improvement in high-impact areas of the body such as the scalp, palms, and soles. Dr. Strober emphasizes risanki...

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2026 issue of JCAD.

James Del Rosso, DO, and Joseph Merola, MD, MMSc, discuss recent advances in the treatment of cutaneous lupus erythematosus (CLE). They emphasize the importance of early detection and appropriate laboratory testing to differentiate between cutaneous-only disease and systemic lupus. They highlight the late-breaking phase 2/3 AMETHYST trial (NCT05531565) data for litifilimab, which showed a significant reduction in skin disease activity in patients with CLE by Week 16.

James Del Rosso, DO, Diego Ruiz Dasilva, MD, and Graham Litchman, DO, MS, discuss the clinical efficacy of bimekizumab (Bimzelx) for patients with severe fingernail psoriasis and concomitant psoriatic arthritis (PsA). They highlighted a case of a 56-year-old woman with extensive dystrophic changes across all 10 fingernails and PsA who had been misdiagnosed and treated for years with antifungals and antibiotics without improvement. After initiating bimekizumab, she achieved complete resolutio...

James Del Rosso, DO, and David Cotter, MD, PhD, discuss the clinical safety and efficacy of nemolizumab for patients with atopic dermatitis (AD). They highlighted a case of an 11-year-old female patient with severe AD who switched from dupilumab (Dupixent) to nemolizumab (Nemluvio). The patient achieved rapid itch reduction and resolution of conjunctivitis and facial erythema. In another case, a 22-year-old female patient with long-standing AD and joint pain switched to nemolizumab, experienc...

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the March 2026 issue of JCAD.

Ted Lain, MD, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, shares his extensive experience with deuruxolitinib (Leqselvi) for the treatment of patients with moderate-to-severe alopecia areata. Drawing on 5 years of long-term extension data, Dr. Lain explains that patients generally maintained hair regrowth they achieved early in treatment, with no loss of effect over time. He emphasizes that this durability is crucial, as patients are often most afraid of losing new...

James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2026 issue of JCAD.

James Del Rosso, DO, and David Cotter, MD, PhD, discuss using gene expression profile testing, such as the AdvanceAD-Tx test, to provide effective treatment for patients with atopic dermatitis. AdvanceAD-Tx allows clinicians to match therapy based on patients’ immune profiles using molecular testing. Drs. Del Rosso and Cotter also review the benefits of using the test not only at baseline, but also throughout treatment in order to tailor their atopic dermatitis therapy and avoid constantly cy...

Amy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses deuruxolitinib for patients with alopecia areata. She highlights its 8-week efficacy compared to placebo in clinical trials. The medication provided significant improvement in hair regrowth at the 8-mg dose, with minimal adverse events. She emphasized the need to perform standard baseline and intermittent lab tests in patients, similar to other Janus kinase inhibitors.

Graham Litchman, DO, MS, a board-certified dermatologist at Vivida Dermatology in Las Vegas, Nevada, discusses a patient case involving a 54-year-old female patient with psoriasis who did not respond well to conventional treatments or systemic steroids. Dr. Lichtman introduced her to risankizumab (Skyrizi), explaining its mechanism of action, adverse events, and dosing schedule. The patient experienced significant improvement by the 3-month mark, with most plaques disappearing. After 1 year o...

James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2026 issue of JCAD.

Dr. Aaron Farberg, a board-certified dermatologist and founder of Bear Dermatology in Dallas, Texas, discusses the evolving treatment landscape for alopecia areata with a focus on Janus kinase inhibitors and how he has used this type of treatment in his practice.

Dr. Mostaghimi discusses the speed and depth of efficacy of deuruxolitinib for providing hair regrowth in patients with severe alopecia areata.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the November 2025 issue of JCAD.

Drs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the root of this condition.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2025 issue of JCAD.

Dr. Cotter discusses providing rapid hair regrowth in patients with alopecia areata.

Dr. Cotter discusses results of an expert consensus panel of the 31-gene expression profile test for patients with Melanoma.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2025 issue of JCAD.

Dr. Cotter discusses providing effective treatment for patients with alopecia areata

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2025 issue of JCAD.

Dr. Del Rosso discusses advancements in photoprotection formulations, as well as recent FDA approvals that have expanded treatment options for rosacea and psoriasis.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2025 issue of JCAD.

In this extended cut from JCAD’s recent Journal Review video series, Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2025 issue of JCAD.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2025 issue of JCAD.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2025 issue of JCAD.

Dr. James Del Rosso discusses a recent supplement that reviews insights about the challenges faced by both patients and clinicians in managing vitiligo.

Dr. Del Rosso discusses potential adverse events that can occur when treating patients with trimethoprim-sulfamethoxazole.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2025 issue of JCAD.

Dr. Del Rosso reviews some of the most impactful research developments and drug approvals seen by the dermatology world in 2024.

Dr. Del Rosso discusses warning signs of serious adverse events related to trimethoprim-sulfamethoxazole prescribed to patients with acne.

Dr. Song provides helpful clinical tips for treating patients with methotrexate.

Dr. Song provides an extensive overview of what’s new and emerging in atopic dermatitis treatment.

Dr. Del Rosso discusses three exciting new indications for drugs in dermatology and how these approvals will impact clinical practice.

Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2024 issue of JCAD.

Dr. Kircik discusses a recent FDA-approval of an IL-17 inhibitor that has demonstrated to be safe and effective in patients with psoriasis.

Dr. Del Rosso discusses how to provide the correct treatment for the various presentations of psoriasis along with the impact psoriatic arthritis can have on these patients.

Dr. Gelfand discusses how to treat patients with psoriasis in terms of cardiovascular risk. He encourages clinicians to educate their patients about these events and the potential side effects they present.

Dr. Del Rosso discusses ways in which he’s modified his consultation style when speaking to patients with psoriasis who are about to commence treatment with a biologic.

George Martin, MD, discusses the specific role TNF inhibitors play for the treatment of psoriasis along with an important safety implication to be aware of for treating patients during pregnancy.

Dr. Del Rosso discusses biologic options for treating patients with psoriasis and psoriatic arthritis as well as pregnant patients.

Dr. Stein Gold discusses insights from clinical trials on new and upcoming systemic agents for psoriasis, including deucravacitinib and bimekizumab.

George Martin, MD, discusses TNF inhibitors for the treatment of psoriasis and how these classic biologic agents currently fit into the ever-expanding arsenal of drugs for psoriasis.

Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, reviews the mechanisms of action of currently available treatments for atopic dermatitis, including JAK inhibitors and biologic medications, and details how these medications work differently to reduce inflammation associated with the disease.

Nicole Keeter, MSHS, PA-C, describes how to implement various JAK inhibitors into practice for the treatment of atopic dermatitis, psoriasis, and alopecia areata. She discusses how utilizing these JAK inhibitors in the treatment of atopic dermatitis has shown to provide a rapid decrease in symptoms, particularly pruritus.

After reviewing notable safety considerations for systemic and topical Janus kinase inhibitors for patients with atopic dermatitis, Nicole Keeter, PA-C, describes steps she has taken to become more comfortable prescribing these agents to her patients with AD and discusses important tips for counseling these patients on adverse events and black box warnings.

Dr. James Del Rosso reviews various common treatments for atopic dermatitis, specifically topical agents that have demonstrated effectiveness for patients.

Peter Lio, MD, Assistant Professor of Clinical Dermatology and Pediatrics at Northwestern University’s Feinberg School of Medicine, discusses the development of JAK inhibitors over the years, and reviews the increase in reliability among both oral and topical treatments for atopic dermatitis.

Dr. James Del Rosso discusses the benefits of topical JAK inhibitors over oral JAK inhibitors for the treatment of atopic dermatitis.

Lisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist with Ada West Dermatology in Boise, Idaho, reviews the role that Janus kinases (JAKs) play in the inflammatory process and the benefits of inhibiting this enzyme when treating patients with atopic dermatitis. She also elaborates upon her experiences using the newly approved JAK inhibitors in her own patients. Dr. Swanson then outlines things to consider before starting patients on JAK inhibitors.

Lisa Swanson, MD, a board-certified dermatologist and pediatric dermatologist with Ada West Dermatology in Boise, Idaho, discusses how she intends to incorporate newly approved JAK inhibitors into her atopic dermatitis treatment algorithm and her strategies for patient counseling when treating with these agents.

Dr. Day discusses the effect of stress on hair health.

Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses how he addresses questions from his patients with AD regarding potential adverse events and warnings associated with treatments for AD.

Douglas DiRuggiero, DMSc, PA-C, discusses the exciting renaissance occurring in the realm of topical treatments for atopic dermatitis.

Matthew Zirwas, MD, provides guidance on speaking with patients with atopic dermatitis about treating their condition with topical JAK inhibitors.

Douglas DiRuggiero, DMSc, PA-C, discusses the mechanism of action and efficacy of topical and systemic JAK inhibitors for the treatment of atopic dermatitis.

Matthew Zirwas, MD, discusses the efficacy, benefits, and safety profile of topical and systemic JAK inhibitors for the treatment of atopic dermatitis.